Inclusion Criteria:

- Histologically confirmed locally advanced or metastatic colorectal cancer.

- Measurable or evaluable disease according to the Response Evaluation Criteria in
Solid Tumors (RECIST)

- ECOG performance status ≤ 2

- Age 18 - 72 years

- Patients with de novo refractory disease (progression of disease as best response at
1st line therapy with FOLFOX/Avastin)

- Adequate liver (Bilirubin ≤ 1.5 UNL, SGOT/SGPT ≤ 4 UNL, ALP ≤ 2.5 UNL),renal
(Creatinine ≤ 1.5 UNL) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function

- Patients must be able to understand the nature of this study

- Written informed consent

Exclusion Criteria:

- History of serious cardiac disease (unstable angina, congestive heart failure,
uncontrolled cardiac arrhythmias).

- History of myocardial infarction or stroke within 6 months.

- Clinically significant peripheral vascular disease.

- History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess
within 28 days prior to Day 0.

- Presence of central nervous system or brain mets.

- Evidence of bleeding diathesis or coagulopathy.

- Patients with known hypersensitive reaction to cetuximab

- Blood pressure > 150/100 mmHg.

- Pregnant or lactating woman.

- Life expectancy < 3 months.

- Previous radiotherapy within the last 4 weeks or > 25% of bone marrow.

- Metastatic infiltration of the liver >50%.

- Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction
or total colectomy.

- Active infection requiring antibiotics on Day 1.

- Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
cancer.

- Psychiatric illness or social situation that would preclude study compliance.